Iboga is a shrub native to Central West Africa whose root bark contains powerful psychoactive compounds, most notably ibogaine. Indigenous to Gabon, Cameroon, and the Congo, the plant has been used for centuries in spiritual ceremonies and, more recently, has drawn global attention for its potential to interrupt opioid addiction. It remains illegal in the United States and several other countries, though clinics in Mexico, New Zealand, and parts of Europe offer ibogaine-based treatments.
The Plant and Where It Grows
Tabernanthe iboga is a perennial rainforest shrub in the dogbane family. It was first formally classified about 140 years ago, though French and Belgian explorers had encountered it in Central West Africa decades earlier. The plant produces small, yellowish-orange fruit, but the root bark is the part that matters pharmacologically. That bark contains a complex mix of alkaloids, with ibogaine being the most abundant at roughly 6% of the root bark’s dry weight (though concentrations can range widely, from less than 1% to over 11% depending on the specimen). Smaller amounts of related compounds like ibogamine, ibogaline, and voacangine round out the alkaloid profile.
This natural variability is one reason raw root bark is considered unpredictable as a medicine. Two batches harvested from different plants, or even different parts of the same plant, can deliver very different doses of active compounds.
Sacred Plant of the Bwiti Tradition
In Gabon, iboga is inseparable from Bwiti, a spiritual tradition that functions as an initiatory rite of passage, a philosophy, and a way of life. Bwiti traces its origins to the Pygmy peoples, the earliest inhabitants of the equatorial forest, and centers on the worship of ancestors and the forest itself. The Tsogho people are believed to have inherited the practice from the Pygmies, and over time other ethnic groups, including the Fang and Simba, adopted and adapted it.
During initiation ceremonies, participants consume large amounts of iboga root bark to induce intense, prolonged visionary states that can last 24 hours or more. These experiences are understood as encounters with ancestors and the spirit world, marking a person’s transition into adulthood or deeper spiritual knowledge. The plant is considered sacred (“bois sacré”) and remains a cornerstone of Gabonese cultural identity.
How Ibogaine Affects the Brain
Ibogaine interacts with multiple brain systems simultaneously, which is part of what makes it unusual among psychoactive substances. One mechanism that researchers have focused on involves a protein called GDNF (glial cell line-derived neurotrophic factor), which supports the health and growth of dopamine-producing neurons. Ibogaine appears to boost GDNF levels in brain regions tied to reward and motivation. This increase may trigger a self-sustaining cycle of GDNF production that persists long after ibogaine itself has been metabolized, potentially reversing some of the neurological changes caused by chronic drug use.
Once ingested, the liver converts ibogaine into a metabolite called noribogaine, which stays active in the body for days to weeks. This long-lasting metabolite is thought to be responsible for much of the sustained reduction in cravings that some people report.
Evidence for Addiction Interruption
Ibogaine’s most studied application is as a treatment for opioid dependence. In survey-based research of people who received ibogaine for opioid problems, 80% reported that it eliminated or drastically reduced withdrawal symptoms, often within one to three hours of ingestion. Full resolution of withdrawal typically occurred within 34 hours. Half of participants experienced reduced cravings lasting at least a week, and 25% reported craving reduction lasting three months or longer.
The outcomes for sustained abstinence are notable for a single-dose treatment. Thirty percent of participants reported never using opioids again after ibogaine treatment, and over half of those abstainers maintained sobriety for at least a year. At the time of follow-up, 41% of all participants had been abstinent for more than six months. These numbers come from observational studies rather than randomized controlled trials, so they should be interpreted with some caution, but they have been consistent enough to fuel growing clinical interest.
Serious Cardiac Risks
The most dangerous known effect of ibogaine is its impact on the heart’s electrical system. It can dramatically prolong the QT interval, a measure of how long the heart takes to reset between beats. When that interval stretches too far, the heart becomes vulnerable to a chaotic, life-threatening rhythm called torsades de pointes, which can lead to cardiac arrest.
In one published case, a 61-year-old man developed a heart rate of 270 beats per minute after taking a large dose of ibogaine, requiring emergency defibrillation. His QT interval reached 714 milliseconds (normal is under 450 for men), and it took seven full days for his heart rhythm to return to normal. This is among the most extreme cases documented, but it illustrates the ceiling of risk.
Reviews of ibogaine-associated fatalities have found that nearly all deaths involved people with pre-existing conditions: coronary artery disease, an enlarged heart, high blood pressure, or liver damage from hepatitis or cirrhosis. Low potassium was detectable in every fatality where it was tested, and low magnesium was present in half. These electrolyte imbalances, common in people with long histories of addiction or alcoholism, appear to amplify ibogaine’s cardiac effects significantly. A history of abnormal heart rhythms, use of other drugs (particularly opiates or cocaine) around the time of treatment, and certain genetic variations in heart ion channels all increase the danger.
Forms of Iboga Used in Treatment
Iboga-derived treatments exist on a spectrum of refinement. Raw root bark is the traditional form, containing the full mix of alkaloids but with highly variable potency. Total alkaloid extract concentrates all the alkaloids from the bark into a more predictable form. Purified ibogaine hydrochloride isolates the single compound ibogaine and offers the most precise dosing, which is what most clinical providers use.
The choice of form matters for safety. Because raw root bark can contain anywhere from 0.6% to 11.2% ibogaine by weight, calculating an accurate dose from bark alone is difficult. Purified ibogaine removes that guesswork, though it also removes the other alkaloids that some practitioners believe contribute to the overall effect.
Legal Status Around the World
Ibogaine is a Schedule I controlled substance in the United States, placing it in the same regulatory category as heroin and psilocybin. Unlike psilocybin or cannabis, no U.S. state has moved to decriminalize it. It is also illegal in Belgium, France, Ireland, Israel, Italy, Norway, Sweden, and Switzerland.
Several countries take a more permissive approach. Australia, Finland, New Zealand, and Uruguay allow ibogaine use outright. Brazil, Canada, Denmark, Hungary, and South Africa permit it as a controlled substance available by prescription. In Mexico, the Netherlands, Germany, and Gabon, there are no specific regulations governing ibogaine, which is why treatment clinics have clustered in those countries, particularly Mexico. Spain and Brazil are currently conducting Phase II clinical trials to formally evaluate ibogaine’s safety and effectiveness.
Most people seeking ibogaine treatment from the U.S. or Europe travel to clinics in Mexico or the Netherlands. The quality and medical oversight at these facilities varies enormously, from hospital-grade cardiac monitoring to minimal screening, making the choice of provider one of the most consequential safety decisions a person can make.